Pharmacoeconomic evaluation of the modern nasal corticosteroids for the allergic rhinitis treatment.
DOI:
https://doi.org/10.26641/2307-0404.2018.1.124949Keywords:
the allergic rhinitis, pharmacoeconomic assessment, nasal corticosteroids, pharmacotherapyAbstract
The increase of allergic rhinitis incidence is an actual problem for industrial cities. The literature data on allergic rhinitis incidence in countries of Europe andUkrainewas analyzed. According to different authors, the allergic rhinitis is registered in 12-24% of the inhabitants of the Russian Federation, 26-40% - of the USA, 24-32% - of France, 16% – of the UK, and 19% – of Denmark. There were distinguished three main clinical forms of allergic rhinitis: light, moderate and heavy. General pharmacotherapy principles of the light and moderate forms of allergic rhinitis course are presented in the current article. There were indicated medicines for the first-line therapy of allergic rhinitis group "R01AD" - the medicines acting on the respiratory system, decongestants and other drugs for topical use in diseases of the nasal cavity, corticosteroids. The assortment of nasal corticosteroids is presented by mometasone (13 trade names), beclamethasone (2 trade names), fluticasone propionate (5 trade names). It is also shown that 95.6% of the nasal corticosteroids is imported from 9 countries, mainly fromIndiaandBelgium. The Ukrainian spray Forinex produced by Pharmac is the only representative among the R01AD group, but unfortunately, according to pricing range is not a drug of choice among nasal corticosteroids. The received data testify to the risk of inclusion of only imported drugs in the insurance list and the low replacement rate by the Ukrainian drug for treatment of the allergic rhinitis.
References
Vaskova LB, Musyna NZ. [Methods and methods of pharmacoeconomic research]. Moskva, HEOTAR-Medya. 2007;112. Russian.
Zabolotnyi DY. [Epidemiology, diagnosis and treatment of allergic rhinitis]. Zdorovia Ukrainy. 2009;9(1):9. Russian.
Vorobev PA, Avksenteva MV, Borysenko OV, et al. [Clinical and economic analysis]. Moskva, NiuDYAMED. 2008;778. Russian.
Makarenko OV, Solomko DS. [Pharmacoeconomic evaluation of the treatment of allergic rhinitis]. Farmakolohiia ta likarska toksykolohiia. 2014;3(39):82-87. Russian.
Izquierdo-Domínguez A, Valero AL, Mullol J. Comarative anal I of allergic rhiniti in children and adult. Curr. Allerg Athma R. 2013;13(2):142.
Hwang PH, Lin B, Weiss R, Atkins J, Johnson J. Cryosurgical posterior nasal tissue ablation for the treatment of rhinitis. Int Forum Allergy Rhin. 2017;7(10):952-6.
Fernandes SSC, Andrade CR, Alvim CG, Camargos PAM, Ibiapina CDC. Epidemiological trends of allergicdiseases in adolescents. J Bras Pneumol. 2017;43(5):368-72.
Numminen J. Allergic rhinitis. Duodecim. 2017;133(5):473-8.
Szelenyi I. Allergic rhinitis: meaningful and less meaningful combination treatments including reminiscences. Pharmazie. 2014;69(6):414-6.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
